If we can measure brain health better, we can develop better treatments.

For years, the pharmaceutical industry has struggled to develop new treatments for brain disorders. Not because of a lack of ideas, but because researchers haven’t been able to see what’s really happening in the brain.

Traditional clinic visits and assessments only provide subjective snapshots in time — not the longitudinal, objective data required to understand whether a disease is progressing or a therapy is working.

This problem was brought into sharp focus at the Dementia Discovery Fund’s (DDF) Annual Forum in 2019, where leaders from pharma highlighted a clear need: the ability to capture frequent, reliable objective measures of brain function across multiple domain including EEG.

A Shared Vision Takes Shape

To explore what an ideal solution might look like, DDF convened a working group comprised of scientists from major pharma companies to address this unmet need. This group aligned on six key requirements for a platform that could meaningfully transform CNS trials — with a broader vision of improving outcomes for patients. 

Around this time, BrainWaveBank Ltd. was already building technology that aligned with this vision — an easy-to-use EEG headset, synchronized to cognitive assessments on a tablet that can be deployed in clinic or at home, and Al-powered analytics to interpret the data.

Bringing It All Together

With funding from DDF and LifeArc, these innovations were combined in 2020 to create Cumulus Neuroscience. The company built NeuLogig^®, a single, unified platform designed to meet all six requirements defined by the DDF working group.

To ensure this new platform could meet pharma industry needs, feasibility studies were executed in collaboration with leading scientists from ten global pharma companies. Today, this group is known as the Cumulus Pharma Advisory Group (CPAG).